Masahiko Umei

Masahiko Umei

Auto-generated profile, based on publicly available information

Masahiko Umei

Department of Cardiovascular Medicine (H.Y., H.A., Q.L., M.U., H.K., R.M., A.S., S.O., T.U., A.S.-K., K.U., N.T.), Graduate School of Medicine, the University of Tokyo, Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
HYHiroki Yagi
Hiroki Yagi
HAHiroshi Akazawa
Hiroshi Akazawa
QLQing Liu
Qing Liu
KYKimiko Yamamoto
Kimiko Yamamoto
KNKan Nawata
Kan Nawata
IKIssei Komuro
Issei Komuro
BACKGROUND: Marfan syndrome (MFS) is an inherited disorder caused by mutations in the FBN1 gene encoding fibrillin-1, a matrix component of extracellular microfibrils. The main cause of morbidity and mortality in MFS is thoracic aortic aneurysm and dissection, but the underlying mechanisms remain undetermined. METHODS: To elucidate the role of endothelial XOR (xanthine oxidoreductase)–derived reactive oxygen species in aortic aneurysm progression, we inhibited in vivo function of XOR either by endothelial cell (EC)–specific disruption of the Xdh gene or by systemic administration of an XOR inhibitor febuxostat in MFS mice harboring the Fbn1 missense mutation p.(Cys1041Gly). We assessed the aberrant activation of mechanosensitive signaling in the ascending aorta of Fbn1 C1041G/+ mice. Further analysis of human aortic ECs investigated the mechanisms by which mechanical stress upregulates XOR expression. RESULTS: We found a significant increase in reactive oxygen species generation in the ascending aorta of patients with MFS and Fbn1 C1041G/+ mice, which was associated with a significant increase in protein expression and enzymatic activity of XOR protein in aortic ECs. Genetic disruption of Xdh in ECs or treatment with febuxostat significantly suppressed aortic aneurysm progression and improved perivascular infiltration of macrophages. Mechanistically, mechanosensitive signaling involving FAK (focal adhesion kinase)–p38 MAPK (p38 mitogen-activated protein kinase) and Egr-1 (early growth response-1) was aberrantly activated in the ascending aorta of Fbn1 C1041G/+ mice, and mechanical stress on human aortic ECs upregulated XOR expression through Egr-1 upregulation. Consistently, EC-specific knockout of XOR or systemic administration of febuxostat in Fbn1 C1041G/+ mice suppressed reactive oxygen species generation, FAK–p38 MAPK activation, and Egr-1 upregulation. CONCLUSIONS: Aberrant activation of mechanosensitive signaling in vascular ECs triggered endothelial XOR activation and reactive oxygen species generation, which contributes to the progression of aortic aneurysms in MFS. These findings highlight a drug repositioning approach using a uric acid–lowering drug febuxostat as a potential therapy for MFS.

1 January 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
HYHiroki Yagi
Hiroki Yagi
HAHiroshi Akazawa
Hiroshi Akazawa
QLQing Liu
Qing Liu
SISayo M. Ito
Sayo M. Ito
MUMasahiko Umei
Masahiko Umei
IKIssei Komuro
Issei Komuro
BACKGROUND: Marfan syndrome is an inherited disorder caused by FBN1 gene mutations, which can lead to thoracic aortic aneurysm and dissection. Selective AT 1 (angiotensin II type 1) receptor blockade is a preventive option against Marfan syndrome aortopathy, and recent clinical studies demonstrated that the inhibitory effect of an ARB (AT 1 receptor blocker) losartan on aortic aneurysm growth is equivalent to that of β-blockers. At present, several ARBs are clinically available, and they have drug-specific differences in pharmacological properties. Especially, inverse agonism of ARBs has potential benefits for cardiovascular protection, but its impact on Marfan syndrome aortopathy remains poorly understood. METHODS: Candesartan-7H is a candesartan derivative that lacks the carboxyl group critical for inverse agonist activity and works as a neutral antagonist for the AT 1 receptor. Candesartan cilexetil (1 mg/kg per day), candesartan-7H (1 or 20 mg/kg per day), or vehicle was administered to Fbn1 C1041G/+ mice, and aortic dilatation was analyzed using echocardiography, histological staining, and in situ MMP (matrix metalloproteinase) assay. Activation of TGF-β (transforming growth factor β) signaling and mechanosensitive signaling was studied using Western blot and immunohistochemical analysis. RESULTS: Candesartan cilexetil (1 mg/kg per day) and candesartan-7H (20 mg/kg per day) lowered blood pressures equally in Fbn1 C1041G/+ mice. Progressive dilatation of the aorta in association with aortic wall thickening, degeneration of elastic fibers, deposition of collagen, MMP activation, and TGF-β signaling activation in Fbn1 C1041G/+ mice was significantly suppressed by treatment with candesartan cilexetil (1 mg/kg per day), but not by candesartan-7H, even at 20 mg/kg per day. In addition, candesartan cilexetil, but not candesartan-7H, suppressed activation of mechanosensitive signaling involving focal adhesion kinase, p38 mitogen-activated protein kinase, and early growth response-1 in the ascending aorta of Fbn1 C1041G/+ mice. CONCLUSIONS: Our findings support a crucial role of inverse agonist activity of ARB for the prevention of mechanical stress-induced AT 1 receptor activation and aortic aneurysm progression in Marfan syndrome mice.

1 January 2026 in Open Heart
Verified
Journal Article
Open access
PDF file
MUMasahiko Umei
Masahiko Umei
GDGerhard Paul Diller
Gerhard Paul Diller
MBMargarita Brida
Margarita Brida
TATuan-Chen Aw
Tuan-Chen Aw
AHAndreas Hoschtitzky
Andreas Hoschtitzky
MGMichael A Gatzoulis
Michael A Gatzoulis
Objective: Syndromic conditions are frequently associated with congenital heart disease (CHD). Their distribution, recognition and prognostic impact in adults with CHD (ACHD) remain poorly characterised due to limited assessment beyond childhood. Methods: We retrospectively analysed 9826 patients with ACHD from a tertiary ACHD centre. Syndromic conditions were identified from clinical records and categorised as chromosomal, single-gene or other syndromes. Clinical characteristics, comorbidities and CHD complexity were compared between syndromic and non-syndromic patients. Multivariable Cox regression was used to evaluate associations with all-cause mortality. Results: Of 9826 patients, 1069 (10.9%) had a syndromic diagnosis. Marfan syndrome (4.1%) and Down syndrome (3.6%) were the most common, followed by Noonan syndrome (0.7%) and 22q11.2 deletion syndrome (0.7%). Syndromic patients were younger (median 34 vs 39 years), had higher rates of pulmonary arterial hypertension (15% vs 5.9%) and sleep apnoea (7.4% vs 2.8%), but fewer traditional cardiovascular risk factors. Down syndrome clustered with atrioventricular septal defect and 22q11.2 deletion with conotruncal defects. In Tetralogy of Fallot, 4.3% had 22q11.2 deletion, mostly diagnosed in childhood; among those without prior diagnosis, most were neither clinically suspected nor tested in adulthood, suggesting under-recognition compared with paediatric cohorts. A syndromic diagnosis was independently associated with higher all-cause mortality (HR 2.06, 95% CI 1.76 to 2.42, p<0.001). Conclusions: We present herewith our institutional ACHD data showing that approximately 1 in 10 patients had a syndromic condition, which was clinically relevant in many respects, cardiovascular or other, including overall mortality. We submit that improved recognition and expanded access to genetic screening may provide additional information relevant to risk stratification and long-term outcome in this growing patient population.

12 August 2026 in International Journal of Cardiology Congenital Heart Disease
Verified
Journal Article
Open access
NSNaoto Shingu
Naoto Shingu
TSTomoyasu Suenaga
Tomoyasu Suenaga
AIAyako Ishikita
Ayako Ishikita
SASoshun Asakawa
Soshun Asakawa
MUMasahiko Umei
Masahiko Umei
KAKohtaro Abe
Kohtaro Abe
Mechanical valve thrombosis is a serious complication in adults with congenital heart disease (ACHD). Although low-dose thrombolytic therapy has emerged as a potential alternative to surgery, evidence in ACHD patients with right-sided mechanical valve thrombosis remains limited. We evaluated the feasibility and safety of a standardized low-dose thrombolytic protocol in this population. We retrospectively reviewed consecutive ACHD patients with right-sided mechanical valve thrombosis treated at our institution between 2022 and 2025. Diagnosis was based on fluoroscopic, echocardiographic, and computed tomography findings. All patients received a standardized low-dose alteplase regimen (25 mg over 6 h). Treatment efficacy was assessed primarily by restoration of prosthetic leaflet mobility on fluoroscopy. Five patients were included: four with mechanical pulmonary valves and one with a mechanical tricuspid valve. Thrombosis occurred a median of 2.3 years after valve replacement, and all patients had subtherapeutic anticoagulation (international normalized ratio <2.0) during the preceding month. At presentation, four patients were in New York Heart Association functional class II and one in class III. Following a median of 5 days of thrombolytic therapy, complete restoration of prosthetic leaflet mobility was achieved in all patients. No major bleeding or thromboembolic complications occurred. During a median follow-up of 0.7 years, no recurrent valve thrombosis was observed. Standardized low-dose thrombolytic therapy was safe and feasible in this case series and may provide a non-surgical treatment option for ACHD patients with right-sided mechanical valve thrombosis.

6 October 2026 in European Heart Journal
Verified
Journal Article
Closed access
MUMasahiko Umei
Masahiko Umei
GDGerhard-Paul Diller
Gerhard-Paul Diller
MBMargarita Brida
Margarita Brida
TATuan-Chen Aw
Tuan-Chen Aw
AHAndreas Hoschtitzky
Andreas Hoschtitzky
MGMichael A Gatzoulis
Michael A Gatzoulis
Background and Aims: With improved survival, adults with congenital heart disease (ACHD) increasingly face acquired cardiovascular risk factors; however, their impact on late mortality remains incompletely defined. This study aimed to evaluate the contribution of acquired cardiovascular risk factors to mortality in ACHD. Methods: A total of 9826 ACHD patients (mean age 39.0 ± 16.4 years; 50.3% male) who attended our tertiary centre between 2000 and 2024 were retrospectively analysed. Clinical and demographic data were obtained from a prospectively maintained database. Cox proportional hazards models were used to assess associations between risk factors and all-cause mortality. Results: During a median follow-up of 10.0 years (98 764 patient-years), 1371 patients died (mortality rate 1.39% per patient-year). In multivariable analysis, older age (hazard ratio [HR] 1.07 per year; P < .001), male sex (HR 1.30; P = .026), greater lesion complexity (HR 2.12; P < .001), coronary artery disease (HR 1.78; P = .005), sleep apnoea (HR 2.22; P < .001), depression (HR 1.45; P = .010), and current smoking (HR 1.67; P < .001) were independently associated with higher mortality, while higher income was associated with lower mortality risk. Conclusions: Both congenital lesion complexity and acquired comorbidities are associated with late mortality in ACHD. These data support the need for comprehensive, multidisciplinary management that incorporates timely modification of general cardiovascular and other risk factors alongside congenital heart disease-specific care.